Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Winter Park, FL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Conyers, GA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Conyers, GA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
River Forest, IL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
River Forest, IL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Skokie, IL
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Skokie, IL
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Newburgh, IN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Newburgh, IN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Iowa City, IA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Lexington, KY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Lexington, KY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Sunset, LA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Sunset, LA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
Fall River, MA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
Fall River, MA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
North Dartmouth, MA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Minneapolis, MN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Plymouth, MN
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Plymouth, MN
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Saint Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Charles, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Charles, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fremont, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fremont, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Lincoln, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Omaha, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Papillion, NE
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Papillion, NE
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cherry Hill, NJ
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Great Neck, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Massapequa, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Massapequa, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
New Windsor, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
New Windsor, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
New York, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
New York, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Syracuse, NY
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Charlotte, NC
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Columbus, OH
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Medford, OR
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Medford, OR
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Medford, OR
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Medford, OR
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Oregon City, OR
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Oregon City, OR
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
Portland, OR
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Langhorne, PA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Langhorne, PA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis
mi
from
Pittsburgh, PA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Pottstown, PA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Pottstown, PA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Tipton, PA
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Tipton, PA
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
East Providence, RI
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
East Providence, RI
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Fort Mill, SC
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Fort Mill, SC
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Rock Hll, SC
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Rock Hll, SC
Click here to add this to my saved trials
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated:  8/20/2013
Novartis Investigative Site
mi
from
Denton, TX
NVA237 BID Versus Placebo Twelve-week Efficacy Study
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status: Enrolling
Updated: 8/20/2013
Novartis Investigative Site
mi
from
Denton, TX
Click here to add this to my saved trials